Sugi Predict

Sugi Predict / Compounds / SCHEMBL295336

SCHEMBL295336

SCHEMBL295336

COc1ccc2c(c1)CC(N)C2

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 7/20 0.74
▸ DRD3 P35462 7/20 0.74
▸ CYP19A1 P11511 1/20 0.51
▸ CA2 P00918 4/20 0.50
▸ CA1 P00915 3/20 0.50
▸ CA12 O43570 2/20 0.50
▸ CA7 P43166 2/20 0.50
▸ CA14 Q9ULX7 2/20 0.50
▸ KDM1A O60341 1/20 0.47
▸ KYAT1 Q16773 1/20 0.46
▸ KYAT3 Q6YP21 1/20 0.46
▸ AADAT Q8N5Z0 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ DRD4 P21917 2/20 0.45
▸ MTNR1A P48039 1/20 0.45
▸ MTNR1B P49286 1/20 0.45
▸ DRD1 P21728 1/20 0.44
▸ DRD5 P21918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20541972 1.00 DRD2 (0.74) DRD2DRD3CYP19A1CA2CA1
SCHEMBL20542100 1.00 DRD2 (0.74) DRD2DRD3CYP19A1CA2CA1
SCHEMBL30579427 1.00 DRD2 (0.74) DRD2DRD3CYP19A1CA2CA1
Hydrochloric Acid SCHEMBL1788371 0.98 DRD2 (0.72) DRD2DRD3CYP19A1CA2CA1
SCHEMBL264631 0.85 DRD2 (0.87) DRD2DRD3CYP19A1CA2CA1
SCHEMBL267102 0.85 DRD2 (1.00) DRD2DRD3CYP19A1CA2CA1
SCHEMBL30416676 0.85 DRD2 (0.87) DRD2DRD3CYP19A1CA2CA1
SCHEMBL354006 0.85 DRD2 (1.00) DRD2DRD3CYP19A1CA2CA1
SCHEMBL19900934 0.85 DRD2 (0.87) DRD2DRD3CYP19A1CA2CA1
SCHEMBL268141 0.85 DRD2 (1.00) DRD2DRD3CYP19A1CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325500-A1 USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING COCAINE ADDICTION CLEARMIND MEDICINE INC (IL) 2025-10-23 — — US claimed
US-20250302773-A1 COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF Clearmind Medicine Inc. (CA) 2025-10-02 — — US claimed
US-20250288541-A1 BINGE BEHAVIOR REGULATORS CLEARMIND LABS CORP. (CA) 2025-09-18 — — US claimed
US-12357590-B2 Binge behavior regulators Clearmind Medicine Inc. (CA) 2025-07-15 — — US claimed
US-12350242-B2 Binge behavior regulators Clearmind Medicine Inc. (CA) 2025-07-08 — — US claimed
CN-119300814-A Use of 5-methoxy-2-aminoindan (\"MEAI\") in a method for treating cocaine addiction 克力迈医药公司 2025-01-10 — — CN claimed
CN-119212690-A Composition comprising MEAI and N-acylethanolamine and use thereof 克力迈医药公司 2024-12-27 — — CN claimed
US-12064402-B2 Binge behavior regulators Clearmind Medicine Inc. (CA) 2024-08-20 — — US claimed
WO-2024062395-A1 USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME Clearmind Medicine Inc. (IL) 2024-03-28 — — WO claimed
CN-112500301-B Regulator for longitudinal behavior 以西结·戈兰 2024-02-13 — — CN claimed
US-20190054042-A1 BINGE BEHAVIOR REGULATORS CLEARMIND LABS CORP. (CA) 2019-02-21 — — US claimed
US-10137096-B2 Binge behavior regulators CLEARMIND LABS CORP. (CA) 2018-11-27 — — US claimed
US-20180085326-A1 BINGE BEHAVIOR REGULATORS CLEARMIND LABS CORP. (CA) 2018-03-29 — — US claimed
US-9884814-B2 Acylguanidines for treating osteoarthritis MERCK PATENT GMBH (DE) 2018-02-06 — — US claimed
US-20170360067-A1 ALCOHOLIC BEVERAGE SUBSTITUTES CLEARMIND LABS CORP. (CA) 2017-12-21 — — US claimed
EP-3230255-A1 BINGE BEHAVIOR REGULATORS Golan, Ezekiel (CA) 2017-10-18 — — EP claimed
EP-3230256-A1 ALCOHOLIC BEVERAGE SUBSTITUTES Golan, Ezekiel (CA) 2017-10-18 — — EP claimed
WO-2016092547-A1 ALCOHOLIC BEVERAGE SUBSTITUTES GOLAN EZEKIEL (IL) 2016-06-16 — — WO claimed
WO-2016092546-A1 BINGE BEHAVIOR REGULATORS GOLAN EZEKIEL (IL) 2016-06-16 — — WO claimed
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-12-17 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250288541-A1 BINGE BEHAVIOR REGULATORS GABRB3, GABRB2, GABRB1 DRD2 62/4885DRD3 131/4885CYP19A1 2287/4885
US-20180085326-A1 BINGE BEHAVIOR REGULATORS GABRB3, GABRB2, GABRB1 DRD2 62/4885DRD3 131/4885CYP19A1 2287/4885
US-12350242-B2 Binge behavior regulators GABRB3, GABRB2, GABRB1 DRD2 62/4885DRD3 131/4885CYP19A1 2287/4885
US-10137096-B2 Binge behavior regulators GABRB3, GABRB2, GABRB1 DRD2 62/4885DRD3 131/4885CYP19A1 2287/4885
US-12064402-B2 Binge behavior regulators GABRB3, GABRB2, GABRB1 DRD2 62/4885DRD3 131/4885CYP19A1 2287/4885
US-20190054042-A1 BINGE BEHAVIOR REGULATORS GABRB3, GABRB2, GABRB1 DRD2 62/4885DRD3 131/4885CYP19A1 2287/4885
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS CTSG, CTSD, CTSB DRD2 1315/4885DRD3 1897/4885CYP19A1 1665/4885
US-20250302773-A1 COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF SLC18A2, PNMT, DBI DRD2 136/4885DRD3 225/4885CYP19A1 1166/4885
US-12357590-B2 Binge behavior regulators GABRB3, GABRB2, GABRB1 DRD2 62/4885DRD3 131/4885CYP19A1 2287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.